• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer

June 12, 2020 By Chris Newmarker

Bigfoot Biomedical updated logoBigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today.

Malone, an endocrinologist specializing in diabetes, also spent 12 years in clinical practice.

“Jim’s blended experience in medical practice and device development bring a dynamic perspective to our team,” Bigfoot Biomedical CEO Jeffrey Brewer said in a news release. “We are laser-focused on launching Bigfoot Unity, and Jim will play a large role in the regulatory review process, payer partnerships and user experience – from the lens of the healthcare provider.”

“Our goal is to reduce the burden on patients, healthcare providers and payers, so Jim’s experience in these areas is immense,” Brewer said.

Bigfoot is nearly finished with product development and FDA submission for the Bigfoot Unity diabetes management program. Bigfoot Unity is a real-time, dose-decision support system that utilizes proprietary, smartpen caps and integrating Abbott’s continuous glucose monitoring platform.

Company officials expect to submit for a 510(k) clearance for Bigfoot Unity this summer — and launch the program in 2021, pending regulatory clearance.

Early this month, Bigfoot announced it had closed a $55 million Series C financing round led by Abbott (NYSE:ABT).

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Bigfoot Biomedical, Personnel Moves

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS